Monitor serum potassium and renal function 3 days and 1 week after initiation of therapy or dose increase, monthly for 3 months, quarterly for a year, and every 6 months thereafter
Consistent fluid intake supports muscle function and recovery
Semaglutide, a long-acting GLP-1 receptor agonist, for the treatment of type 2 diabetes
In a late-stage trial of Ozempic, which included people with type 2 diabetes, most patients who reported gastrointestinal side effects had mild to moderate symptoms which reduced over time
Licensed UK weight loss medicines including orlistat, semaglutide (Wegovy), and naltrexone/bupropion (Mysimba) have no established direct effect on the menstrual cycle per their UK SmPCs
Not eating enough or delaying meals can also cause levels to drop